Investor Presentation Q1 2023

46 Investor presentation First three months of 2023 Novo Nordisk global insulin market leadership at 46.3% and the global insulin volume market declined by 1.3% North America Operations Market growth: -3.4% MS: 38.1% MS gain/loss': -0.5%-p Sales growth: -18% USA Market growth: -3.5% MS: 37.7% MS gain/loss: -0.4%-p Sales growth: -18% Global Market growth: -1.3% MS 46.3% MS gain/loss': -0.8%-p Sales growth: -11% Novo NordiskⓇ International Operations Market growth: -0.6% MS: 49.2% MS gain/loss: -0.9%-p Sales growth: -8% Market growth: -4.4% MS: 57.5% MS gain/loss¹: 0.4%-p Sales growth: 4% Region China Market growth: 9.4% MS: 46.0% MS gain/loss: -4.6%-p Sales growth: -22% EMEA Market growth: -2.2% MS: 47.4% ROW MS gain/loss: -0.1%-p Sales growth: -5% Source: IQVIA MAT, Feb 2023 volume figures Note: Sales growth for first three months of 2023 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with Feb 2022 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; RoW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong

View entire presentation